Asparaginase has long been recognized as a crucial element in the treatment of pediatric ALL. This
interactive panel session will focus primarily on pegaspargase, providing background on its inclusion in
ALL therapy, and lessons learned. Cases highlighting the practical challenges of administering this drug
and identifying adverse effects will be presented. Furthermore, strategies for continued administration
including alternative asparaginase products will be discussed.
Lee Dupuis, RPh, PhD
Associate Scientist and Clinical Pharmacist
The Hospital for Sick Children, Toronto, ON
Lee has a BSc, BScPhm and MScPhm from the University of Toronto. She completed her pharmacy residency at Sunnybrook Health Sciences Centre and her PhD at the University of Amsterdam. She has held several positions at The Hospital for Sick Children (SickKids) including Coordinator of Drug Information; Manager of Clinical Pharmacy Services, Research & Education; and Clinical Pharmacy Manager – Haematology/Oncology. She is currently an Associate Scientist with the Research Institute,
Sick Kids and the Leslie Dan Faculty of Pharmacy, University of Toronto.
Lee’s research focuses on the supportive care of children with cancer or undergoing bone marrow
transplant with a focus on improving control of chemotherapy-induced nausea and vomiting and creating ways that children can communicate the severity of treatment-related adverse effects. Lee serves on committees within the Children’s Oncology Group, POGO and C17 and on guideline development panels for POGO, American Society of Clinical Oncology, the Dutch Children’s Oncology Group and the Multinational Association of Supportive Care in Cancer.
Paul Gibson, MD, FRCPC
Pediatric Oncologist, Children’s Hospital, London Health Sciences Centre (LHSC), London, ON
Medical Officer, Pediatric Oncology Group of Ontario
Assistant Professor, Western University, London, ON
Dr. Gibson is a graduate of Queen’s University’s Medical School. He completed pediatric residency training at B.C. Children’s Hospital prior to subspecialty training at The Hospital for Sick Children. He joined the Section of Pediatric Hematology and Oncology at Children’s Hospital full time in 2010. He has served as Physician Lead in the LHSC Computerized Provider Order Entry project and is currently a Physician Lead in the PowerChart Oncology project. Dr. Gibson has served as Medical Officer of the Pediatric Oncology Group of Ontario (POGO) since 2015. His role with POGO includes medical support of the POGO Satellite program and membership on the executive oversight committee of the Provincial Pediatric Oncology Planning process.
Stephen Sallan, MD
Chief of Staff, Emeritus
Dana Farber Cancer Institute, Boston, MA
Dr. Stephen E. Sallan is Chief of Staff, Emeritus and the Quick Family Senior Investigator in Pediatric Oncology at Dana-Farber Cancer Institute, and a Professor of Pediatrics at Harvard Medical School. Dr. Sallan is one of the world’s foremost experts on childhood leukemia. His principal contributions include optimizing the use of asparaginase in acute lymphoblastic leukemia (ALL), enhancing outcomes in young adults with ALL, developing “therapeutic windows” for newly diagnosed patients, preventing therapy-related cardiotoxicity, and exploring innovative approaches to the prevention of chemotherapy-induced nausea and vomiting. After completing his education at Wayne State University in Detroit, he trained in pediatrics at Boston Floating Hospital, Children’s Hospital of Philadelphia, and the Hospital for Sick Children, Great Ormond Street, London. Since 1972, he has pursued his clinical and research career at Boston Children’s Hospital and the Dana Farber Cancer Institute.